医学
彭布罗利珠单抗
卡铂
危险系数
吉西他滨
肿瘤科
化疗
内科学
杜瓦卢马布
癌症
顺铂
置信区间
免疫疗法
作者
Thomas Powles,Begoña P. Valderrama,Shilpa Gupta,Jens Bedke,Eiji Kikuchi,Jean Hoffman‐Censits,Gopa Iyer,Christof Vulsteke,Se Hoon Park,Sang Joon Shin,Daniel Castellano,Giuseppe Fornarini,Jian‐Ri Li,Mahmut Gümüş,Nataliya Mar,Yohann Loriot,Aude Fléchon,Ignacio Durán,Alexandra Drakaki,Sujata Narayanan
标识
DOI：10.1056/nejmoa2312117
摘要
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
浮游
HOAN
无极微光
Criminology34
pluto
大力帽子
香蕉诗蕊
spc68
Jared
sswbzh
求助人员
彭于彦祖
嘞是举仔
风清扬
轨迹
yznfly
ShawnJohn
一一
LaTeXer
小青椒
子车茗
寻道图强
Twonej
专注的问寒
皖公网安备34019202002308
